Systemic Immune-inflammation Index (SII) is Useful to Predict Survival Outcomes in Patients with Surgically Resected Non-small Cell Lung Cancer

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2019 Feb 9

PMID 30734516

Citations 46

Authors

Wei Guo

Songhua Cai

Fan Zhang

Fei Shao

Guochao Zhang

Yang Zhou

Liang Zhao

Fengwei Tan

Shugeng Gao

Jie He

Affiliations

Soon will be listed here.

Abstract

Background: The systemic immune-inflammation index (SII) is correlated with patient survival in various types of solid tumors. However, only a few studies have focused on the prognostic value of the SII in patients with surgically resected non-small cell lung cancer (NSCLC).

Methods: This study was a single center retrospective analysis of 569 NSCLC patients who underwent curative lobectomy at the Department of Thoracic Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College between 2006 and 2012. A receiver operating characteristic curve was plotted to compare the discriminatory ability of the SII for overall survival (OS). A Cox proportional hazards regression model was used to perform univariate and multivariate analyses.

Results: The SII, neutrophil-lymphocyte ratio (NLR), and platelet-lymphocyte ratio (PLR) all correlated with OS in NSCLC patients, and the SII was an independent prognostic factor for OS (hazard ratio 1.256, 95% confidence interval 1.018-1.551; P = 0.034). The area under the receiver operating characteristic curve of the SII (0.547) was larger than the NLR (0.541) and PLR (0.531). Furthermore, the SII retained prognostic significance in the lung adenocarcinoma subgroup.

Conclusion: The SII is a promising prognostic predictor for patients with surgically resected NSCLC and retained prognostic significance in the lung adenocarcinoma subgroup. The prognostic value of the SII is superior to the NLR and PLR.

Citing Articles

A novel nomogram for predicting postoperative pneumonia risk in patients with localized bronchiectasis.

Yongsheng C, Lihui K, Xuefeng H, Anbang Q, Xiaoxiao Y, Wenhui C Ther Adv Respir Dis. 2025; 19:17534666251320471.

PMID: 39988984 PMC: 11848899. DOI: 10.1177/17534666251320471.

[Predictive Value of Prognostic Nutritional Index in Prognosis and  Spontaneous Pleurodesis of Patients with Advanced Non-small Cell Lung Cancer  and Malignant Pleural Effusion].

Tan S, Li W, Tian P Zhongguo Fei Ai Za Zhi. 2025; 27(12):931-939.

PMID: 39962848 PMC: 11843482. DOI: 10.3779/j.issn.1009-3419.2024.106.33.

The Effect of Laboratory Parameters on the Hospital Stay and Mortality in Pediatric Patients Who Underwent Lobectomy and Pneumonectomy.

Ulusan A, Danaci H, Elma B, Sanli M, Isik A Medicina (Kaunas). 2025; 61(1).

PMID: 39859008 PMC: 11766857. DOI: 10.3390/medicina61010026.

The Prognostic Value of Systemic Immune-Inflammation Index Supporting Age-Adjusted Charlson Comorbidity Index in Non-Small Cell Lung Cancer Patients with First-Line Platinum-Based Chemotherapy.

Sheng Y, Zhu Q, Dai Q, Gao Y, Bai Y, Liu M Int J Gen Med. 2024; 17:5837-5848.

PMID: 39669219 PMC: 11634787. DOI: 10.2147/IJGM.S486674.

Association between systemic immune-inflammation index and serum neurofilament light chain: a population-based study from the NHANES (2013-2014).

Liu X, Yang Y, Lu Q, Yang J, Yuan J, Hu J Front Neurol. 2024; 15:1432401.

PMID: 39239395 PMC: 11374650. DOI: 10.3389/fneur.2024.1432401.

References

Ma J, Kuzman J, Ray A, Lawson B, Khong B, Xuan S . Neutrophil-to-lymphocyte Ratio (NLR) as a predictor for recurrence in patients with stage III melanoma. Sci Rep. 2018; 8(1):4044. PMC: 5840418. DOI: 10.1038/s41598-018-22425-3. View

Stanger B, Kahn M . Platelets and tumor cells: a new form of border control. Cancer Cell. 2013; 24(1):9-11. PMC: 3743536. DOI: 10.1016/j.ccr.2013.06.009. View

Gooden M, de Bock G, Leffers N, Daemen T, Nijman H . The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011; 105(1):93-103. PMC: 3137407. DOI: 10.1038/bjc.2011.189. View

Fu H, Zheng J, Cai J, Zeng K, Yao J, Chen L . Systemic Immune-Inflammation Index (SII) is Useful to Predict Survival Outcomes in Patients After Liver Transplantation for Hepatocellular Carcinoma within Hangzhou Criteria. Cell Physiol Biochem. 2018; 47(1):293-301. DOI: 10.1159/000489807. View

Pine J, Morris E, Hutchins G, West N, Jayne D, Quirke P . Systemic neutrophil-to-lymphocyte ratio in colorectal cancer: the relationship to patient survival, tumour biology and local lymphocytic response to tumour. Br J Cancer. 2015; 113(2):204-11. PMC: 4506398. DOI: 10.1038/bjc.2015.87. View

Templeton A, Ace O, McNamara M, Al-Mubarak M, Vera-Badillo F, Hermanns T . Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014; 23(7):1204-12. DOI: 10.1158/1055-9965.EPI-14-0146. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

Zhou X, Du Y, Huang Z, Xu J, Qiu T, Wang J . Prognostic value of PLR in various cancers: a meta-analysis. PLoS One. 2014; 9(6):e101119. PMC: 4072728. DOI: 10.1371/journal.pone.0101119. View

Luo H, Ge H, Cui Y, Zhang J, Fan R, Zheng A . Systemic Inflammation Biomarkers Predict Survival in Patients of Early Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiotherapy - A Single Center Experience. J Cancer. 2018; 9(1):182-188. PMC: 5743726. DOI: 10.7150/jca.21703. View

10.

Tong Y, Tan J, Zhou X, Song Y, Song Y . Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. J Transl Med. 2017; 15(1):221. PMC: 5664920. DOI: 10.1186/s12967-017-1326-1. View

11.

Wang L, Wang C, Wang J, Huang X, Cheng Y . A novel systemic immune-inflammation index predicts survival and quality of life of patients after curative resection for esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2017; 143(10):2077-2086. DOI: 10.1007/s00432-017-2451-1. View

12.

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

13.

Gao Y, Zhang H, Li Y, Wang D, Ma Y, Chen Q . Preoperative increased systemic immune-inflammation index predicts poor prognosis in patients with operable non-small cell lung cancer. Clin Chim Acta. 2018; 484:272-277. DOI: 10.1016/j.cca.2018.05.059. View

14.

Wu G, Yao Y, Bai C, Zeng J, Shi D, Gu X . Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patients. Thorac Cancer. 2015; 6(3):275-87. PMC: 4448393. DOI: 10.1111/1759-7714.12178. View

15.

Chen J, Zhai E, Yuan Y, Wu K, Xu J, Peng J . Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017; 23(34):6261-6272. PMC: 5603492. DOI: 10.3748/wjg.v23.i34.6261. View

16.

Peng H, Lin K, He B, Pan Y, Ying H, Hu X . Platelet-to-lymphocyte ratio could be a promising prognostic biomarker for survival of colorectal cancer: a systematic review and meta-analysis. FEBS Open Bio. 2016; 6(7):742-50. PMC: 4932454. DOI: 10.1002/2211-5463.12083. View

17.

Takeuchi H, Kawanaka H, Fukuyama S, Kubo N, Hiroshige S, Yano T . Comparison of the prognostic values of preoperative inflammation-based parameters in patients with breast cancer. PLoS One. 2017; 12(5):e0177137. PMC: 5425200. DOI: 10.1371/journal.pone.0177137. View

18.

Deng M, Ma X, Liang X, Zhu C, Wang M . Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?. Oncotarget. 2017; 8(23):37200-37207. PMC: 5514902. DOI: 10.18632/oncotarget.16553. View

19.

Guo J, Chen S, Chen Y, Li S, Xu D . Combination of CRP and NLR: a better predictor of postoperative survival in patients with gastric cancer. Cancer Manag Res. 2018; 10:315-321. PMC: 5817420. DOI: 10.2147/CMAR.S156071. View

20.

Jackman D, Johnson B . Small-cell lung cancer. Lancet. 2005; 366(9494):1385-96. DOI: 10.1016/S0140-6736(05)67569-1. View